These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 26430832)
1. Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study. Stamatoullas A; Rezine I; Mareschal S; Ménard AL; Lanic H; David M; Daliphard S; Penther D; Lemasle E; Cassuto O; Lenain P; Contentin N; Lepretre S; Jardin F; Bastard C; Tilly H Leuk Lymphoma; 2016; 57(6):1491-3. PubMed ID: 26430832 [No Abstract] [Full Text] [Related]
2. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of azacitidine in myelodysplastic syndromes. Vigil CE; Martin-Santos T; Garcia-Manero G Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213 [TBL] [Abstract][Full Text] [Related]
4. Is there an association between 5-azacitidine and ototoxicity? Malik A; Misbah S; Spaccavento C; Yudelman I J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015 [No Abstract] [Full Text] [Related]
6. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome. Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928 [No Abstract] [Full Text] [Related]
7. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068 [No Abstract] [Full Text] [Related]
8. Azacitidine and the beginnings of therapeutic epigenetic modulation. O'Dwyer K; Maslak P Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335 [TBL] [Abstract][Full Text] [Related]
9. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615 [TBL] [Abstract][Full Text] [Related]
10. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient. Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907 [No Abstract] [Full Text] [Related]
11. Decitabine. Gore SD; Jones C; Kirkpatrick P Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522 [No Abstract] [Full Text] [Related]
12. Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report. Ponard A; Ferreira-Maldent N; Ertault M; Delain M; Amraoui K; Regina S; Jonville-Béra AP; Hérault O; Colombat P; Gyan E J Med Case Rep; 2018 Jul; 12(1):199. PubMed ID: 29966534 [TBL] [Abstract][Full Text] [Related]